DuPont hosts ribbon-cutting for new medical elastomer mixers at Healthcare Industries Materials Site in the U.S.

Celebrating the installation are (left to right) DuPont Project Team Leader Tim Markel, Plant Manager Jessica Snyder, DuPont E&I VP and GM Sam Ponzo, and Saginaw Future President and CEO JoAnn Crary.

“The deployment of these mixers will not only help alleviate supply chain pressure – which in turn supports our customers’ growth – but the expansion will also enhance the well-being of the HIMS community through the creation of six new positions at the site,” said Jessica Snyder, DuPont Healthcare.

DuPont (NYSE:DD) celebrated the inauguration of its new medical elastomers mixers at the Healthcare Industries Materials Site (HIMS) in Hemlock, Michigan, USA, with a formal ribbon-cutting ceremony today. The investment in the new mixers responds to increased supply needs from DuPont™ Liveo™ Healthcare Solutions customers.

The capacity expansion will:

  •     Expand in-house medical-grade silicone elastomer (Liquid Silicone Rubber and High Consistency Rubber) manufacturing capabilities
  •     Enable sustainable growth in Liveo™ medical elastomer product lines serving specialty medical devices along the value chain
  •     Support the strong growth of in-house production of Liveo™ pharmaceutical tubing dedicated to biopharmaceutical processing, and of medical devices and topical blends.

“The deployment of these mixers will not only help alleviate supply chain pressure – which in turn supports our customers’ growth – but the expansion will also enhance the well-being of the HIMS community through the creation of six new positions at the site,” said Jessica Snyder, HIMS Site Leader for DuPont Healthcare.
The 8,000 square foot site expansion was a coordinated effort by DuPont staff and over 10 local contracting companies. With over 52,500 contractor hours logged, all the work was successfully completed without a single safety incident.

The ribbon-cutting event featured a site tour and remarks by Samuel Ponzo, Vice President and General Manager, DuPont Electronics & Industrial, and by JoAnn Crary, President and CEO of Saginaw Future – which recognized DuPont HIMS with an Economic Development Award in 2021.

“DuPont’s new investment in the Healthcare Industries Materials Site (HIMS) will support continued growth and retain jobs in Saginaw County,” said Saginaw Future President JoAnn Crary. “Saginaw Future is proud to be a partner and strong supporter of DuPont HIMS, which is a key producer of materials for critical healthcare applications that improve patient comfort and safety.”

DuPont increasingly is committed to serving the healthcare market, offering high-quality, high-performance solutions; application and material science expertise; and strong regulatory support to address healthcare customers’ specific needs. As previously announced, the company plans additional future healthcare investments, including:

  •     Adding a new overmolded assembly (OMA) press at HIMS
  •     Opening a new healthcare manufacturing site for biopharmaceutical processing tubing in Cooper River, South Carolina, USA
  •     Expanding local manufacturing capabilities in China for biopharmaceutical processing tubing designated for regional sales.

These future investments are intended to be deployed between now and the second half of 2022.

About DuPont™ Liveo™ Healthcare Solutions
DuPont™ Liveo™ is a globally recognized leader in silicone-based technology for a broad range of innovations in medical devices, biopharmaceutical processing and pharmaceutical solutions. DuPont high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information can be found at liveo.dupont.com.

About DuPont Electronics & Industrial
DuPont Electronics & Industrial is a global supplier of new technologies and performance materials serving the semiconductor, circuit board, display, digital and flexographic printing, healthcare, aerospace, industrial, and transportation industries. From advanced technology centers worldwide, teams of talented research scientists and application experts work closely with customers, providing solutions, products and technical service to enable next-generation technologies.

About DuPont
DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at http://www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

Cautionary Statement Regarding Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” and similar expressions and variations or negatives of these words.

On April 1, 2019, the Company completed the separation of the materials science business through the spin-off of Dow Inc., (“Dow”) including Dow’s subsidiary The Dow Chemical Company (the “Dow Distribution”). On June 1, 2019, the Company completed the separation of the agriculture business through the spin-off of Corteva, Inc. (“Corteva”) including Corteva’s subsidiary E. I. du Pont de Nemours and Company (“EID”), (the “Corteva Distribution and together with the Dow Distribution, the “DWDP Distributions”).

On February 1, 2021 the Company completed the divestiture of the Nutrition & Biosciences (“N&B”) business to International Flavors & Fragrance Inc. (“IFF”) in a Reverse Morris Trust transaction (the “N&B Transaction”) that resulted in IFF issuing shares to DuPont stockholders.

On July 1, 2021, DuPont completed the previously announced acquisition of the Laird Performance Materials business, (the “Laird PM Acquisition”).

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which that are beyond DuPont’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the ability to achieve expected benefits, synergies and operating efficiencies in connection with the Laird PM Acquisition within the expected time frames or at all or to successfully integrate the Laird Performance Materials business; (ii) ability to achieve anticipated tax treatments in connection with the N&B Transaction, Laird PM Acquisition or the DWDP Distributions; (iii) changes in relevant tax and other laws; (iv) indemnification of certain legacy liabilities of EID in connection with the Corteva Distribution; (v) risks and costs related to the performance under and impact of the cost sharing arrangement by and between DuPont, Corteva and The Chemours Company related to future eligible PFAS costs; (vi) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (vii) uncertainty as to the long-term value of DuPont common stock; (viii) risks and uncertainties related to the novel coronavirus (COVID-19) and the responses thereto (such as voluntary and in some cases, mandatory quarantines as well as shut downs and other restrictions on travel and commercial, social and other activities) on DuPont’s business, results of operations, access to sources of liquidity and financial condition which depend on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume; and (ix) other risks to DuPont’s business, operations; each as further discussed in detail in and results of operations as discussed in DuPont’s annual report on Form 10-K for the year ended December 31, 2020 and its subsequent reports on Form 10-Q and Form 8-K. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

# # #

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

9/29/21